Johor Bahru, 20 March 2024 – JLand Group Sdn Bhd (JLG), the real estate and infrastructure arm of Johor Corporation (JCorp), has signed a memorandum of understanding with biotechnology powerhouse, ALPS Global Holding Bhd (ALPS) to establish Malaysia’s very own ‘ Silicon Valley’ of biotechnology hub.
With the global biotechnology market sets to skyrocket towards an estimated value of nearly four times its 2020 figure by 2030, the collaboration between JLG & ALPS is anticipated to emerge as Malaysia’s strategic initiative to seize upon this unparalleled growth trajectory. The impending development of the hub is anticipated to generate an estimated gross development value (GDV) of RM980 million.
Nestled within the dynamic circular city of Ibrahim Technopolis (IBTEC) in Sedenak, Johor, the hub is set to emerge as a comprehensive biotechnology and life sciences hub in the coming decade. Spanning vaccine manufacturing and development, genomics, regenerative medicines, immunotherapy and gene editing, this state-of-the-art research hub is primed to tackle the most pressing challenges of healthcare confronting humanity in the present day.
“We applaud ALPS’s achievements thus far and eagerly anticipate exploring more opportunities together. We believe this collaboration will signify a momentous milestone in biotechnology innovation on the global stage, fostering a thriving ecosystem conducive to pioneering research, knowledge exchange, and economic advancement. Set to become one of our forthcoming ventures within IBTEC, the biotechnology hub will revolutionise the sector and serve as a significant addition to our established data centre hub and upcoming artificial intelligence (AI) hub. It will unite new-age industrialists, digital pioneers, and lifelong learners in an advanced environment engineered for sustainable growth, aligned with the New Industrial Masterplan 2030 (NIMP2030) and the National Energy Transition Roadmap (NETR),” said Datuk Sr. Akmal Ahmad, Director of Real Estate & Infrastructure, JCorp / Deputy Chairman, JLG.
The continued advancements in biotechnology hold the potential to reform healthcare, offering more personalised and preventive treatments for a wide spectrum of conditions. From agile startups to industry giants, these entities are driving forward the frontiers of science and medicine, exerting a profound influence on the trajectory of healthcare. With a projected Compound Annual Growth Rate (CAGR) of 16.7% from 2022 to 2030, Asia Pacific region is solidifying its position as the epicentre of biotechnological progress.
Inside BioValley @ IBTEC
Located strategically within the expansive 7,290-acre IBTEC development and with convenient proximity to Singapore, the biotechnology hub is envisioned to be a thriving ecosystem that fosters innovation, collaboration, and growth. It seeks to provide innovative infrastructure, resources, and support services to facilitate the translation of scientific discoveries into practical applications that benefit society. It aims to bring together researchers, entrepreneurs, investors, and industry experts to drive advancements in biotech research, development, and commercialization. Additionally, it intends to attract talent, investment, and partnerships to create a vibrant community dedicated to addressing global challenges in healthcare, innovation, environmental and sustainability.
Spanning across 500,000 square feet of campus-style architecture, the development will unfold three progressive phases: Phase 1 will prioritise the establishment of crucial infrastructure including vaccine manufacturing plant, cell processing centre, and molecular laboratory. Phase 2 will further bolster the ecosystem by nurturing start-up incubators, academic institutions, and research & development (R&D) centres. While Phase 3 will culminate in the creation of a vibrant commercial hub alongside residential developments. Moreover, the biotechnology hub will introduce pioneering services such as regenerative and immunotherapy, as well as initiatives like a clinical trial centre and a medical tourism hub, enhancing its status as a comprehensive and cutting-edge biotechnology hub.
“We are thrilled to join forces with JLG in bringing the biotechnology hub to life and reshaping its landscape, not just within Malaysia but on a global scale. With JLG’s expertise and Johor’s favourable investment climate, we are confident that our collaborative efforts will establish the biotechnology hub as the premier destination for biotechnology solutions, attracting top-tier industry leaders and talent to engage in groundbreaking research initiatives. Together, our dedication is focused on driving innovation and excellence across the entire biotechnology value chain, from upstream processes to downstream activities. Our goal is to revolutionise the industry, enhance patient outcomes, and shape the future of biomedicine for generations to come. Ultimately, we strive to be a leading hub of biotechnological excellence, driving economic growth and societal impact,” added Dato’ Sri Dr. Tham Seng Kong, Group Chief Executive Officer of ALPS.
Through the partnership, JLG will play a pivotal role as both landowner and developer, nurturing an environment conducive to biotechnological endeavours, while ALPS will serve as the anchor tenant and operator, harnessing its established facilities, team of scientists, and extensive global biotechnology networks. The integration of the biotechnology cluster will be focal in advancing the industrial ecosystem at IBTEC. In complementing the success of its existing data centre campus, the forthcoming smart logistics & manufacturing and artificial intelligence hubs, the inclusion of biotechnology hub will actively drive the realisation of a circular economy, harmonising seamlessly with IBTEC’s overarching vision.
The future of biotechnology holds immense promise and potential for transformative breakthroughs across various sectors including healthcare, agriculture, environmental sustainability, and beyond. Like other industries, AI is expected to make significant contributions to various aspects of biotechnology, spanning from enhancing research, drug discovery, diagnostics, and personalised medicine to cutting-edge diagnostics and regenerative treatments. By adeptly navigating challenges and harnessing the immense potential, this field will pave the way for healthier lives for future generations.
About JLand Group Sdn Bhd
JLand Group Sdn Bhd (JLG) is a wholly owned real estate and infrastructure arm of Johor Corporation (JCorp), focusing on spearheading the Group’s real estate and infrastructure businesses. JLG’s portfolio spans across diversified real estate activities and investments, ranging from integrated industrial parks to data centres, logistics hubs, digital infrastructure, smart utilities and cutting-edge innovation centres.
JLG’s core businesses encompass four strategic areas, namely Real Estate Development, Asset Lifecycle Management, Real Estate Investment, and Infrastructure & Utilities. These pillars serve as the cornerstone for maximising value strategically across our businesses and assets, underpinning our strong foothold across various industries. To learn more about our endeavours, please visit www.jlandgroup.com.my or connect with us on LinkedIn.
About ALPS Global Holding Berhad
Alps Global Holding Berhad is a leading biotechnology company dedicated to driving innovation and advancing healthcare solutions. With a focus on research, development, and commercialization of cutting-edge biotechnological products and services, ALPS is committed to improving global health outcomes. Through strategic partnerships, groundbreaking research initiatives, and a commitment to excellence,
ALPS aims to revolutionise the biotech industry and make a positive impact on society. For more information, visit https://alps-holdings.com
Photo Credit: The Edge Malaysia